Affibody Medical Investor Relations

Affibody Relocates to the Karolinska Institute Campus in Solna


September 23, 2019

Affibody Relocates to the Karolinska Institute Campus in Solna

Solna, Sweden, September 23, 2019. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a pipeline of innovative bi- and multi-specific drug projects, today announced its relocation to the Karolinska Institute Campus in Solna.

“Affibody is focused on innovation and our move to the Karolinska Institute Campus is a testimony to our commitment to improve lives of patients by developing patient centric drugs in close collaboration with the scientific and clinical community”, said David Bejker, CEO of Affibody. “We believe that one of the key elements in building a differentiated pipeline and advancing our experimental medicines model is our interaction with high quality scientists and clinicians. The move to Karolinska is a key step in the development of new and exciting candidate drugs based on Affibody’s platforms”.

The new premises are ~3,700 square meters, and are located in the Scheele-laboratory and house a state of the art facility that has been carefully planned and designed to meet our current and future research and development needs. The premises include ample meeting space designed to enable close interaction with current and future collaborators.

“Our premises in the Scheele-laboratory will fuel our further expansion as a research driven company and at the same time put us in the heart of medical science in Northern Europe. Our ambition is to be an active member of the vibrant research community at the Karolinska and we are eager to develop both new relationships as well as deepening our current relationships with the local scientific community in the Stockholm and Uppsala region”, commented Prof. Fredrik Frejd, CSO of Affibody. 

Affibody is a private clinical-stage Swedish biotech company focused on developing into an integrated biopharma company utilizing next generation biotherapeutics based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

The company operates a focused experimental medicine model and currently has three clinical stage programs. The first two are therapeutic programs that target psoriasis and rare Immunoglobulin G (IgG)-mediated autoimmune diseases. The third program is a diagnostic imaging program that is directed primarily towards metastatic breast cancer.

In addition, to its portfolio of innovative drug projects the company offers the half-life extension technology, Albumod™, for outlicensing. Affibody AB is a holding of Patricia Industries. For more information on Affibody, please visit the company’s website at